The USA’s Retrophin (Nasdaq: RTRX) has submitted an unsolicited $95 million takeover proposal to the board of directors of Australian biotech firm Clinuvel Pharmaceuticals, the shares of which rocketed 28% to A$2.15 in mid-morning trading today.
Retrophin has proposed a “scheme of arrangement” for all of the shares of Clinuvel stock that Retrophin does not own for (1) 0.175 Retrophin shares per Clinuvel share, or (2) A$2.17 per share in cash. Retrophin currently owns around 4.88% of Clinuvel, which is developing therapies for rare skin diseases
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze